Cognitive Rehabilitation Program for Intellectual Disability
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how a computerized cognitive rehabilitation program, D-kit/EF1, might assist children with borderline or mild intellectual disabilities. Participants will use the program on an iOS device for 30 minutes, five times a week, over 12 weeks. The study compares the effects of this digital program with a control group that watches educational videos. Children diagnosed with borderline or mild intellectual disabilities who can engage in tablet activities may be suitable candidates. As an unphased trial, this study provides a unique opportunity for children to potentially benefit from innovative cognitive rehabilitation techniques.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that the D-kit/EF1 program is safe for children with intellectual disabilities?
Studies have shown that computerized programs like D-kit/EF1, which assist with thinking skills, are generally safe and well-tolerated. Although specific safety data for D-kit/EF1 is unavailable, similar programs typically pose no significant risks. These programs often use engaging quizzes to enhance brain functions, such as memory and problem-solving, in children with mild intellectual disabilities. Since this trial is exploratory and not focused on a medical procedure or drug, the risks are lower compared to traditional treatments. However, parents or caregivers should supervise the child to ensure safe use of the program.12345
Why are researchers excited about this trial?
Unlike traditional methods for intellectual disability that often focus on behavioral therapy and medication, the D-kit/EF1 program introduces a unique approach by leveraging cognitive rehabilitation through a mobile tablet. Researchers are excited about this treatment because it offers an accessible, tech-driven solution that can be easily incorporated into daily routines. The program involves interactive sessions guided by the participant's caregivers, which fosters a supportive learning environment and encourages consistent engagement. This innovative delivery method not only makes cognitive training more engaging but also empowers caregivers to actively participate in the therapeutic process.
What evidence suggests that the D-kit/EF1 program is effective for intellectual disability?
Research has shown that the D-kit/EF1 program, a computerized tool for cognitive rehabilitation, aims to improve thinking skills in children, such as memory, flexible thinking, and self-control. In this trial, participants in the D-kit/EF1 group will use the program to enhance these skills. Although direct proof of D-kit/EF1's effectiveness for children with intellectual disabilities is not yet available, previous studies suggest that improving these thinking skills can enhance mental abilities in children with mild intellectual challenges. The program's fun, game-like quizzes aim to make learning enjoyable and effective for young users.12356
Who Is on the Research Team?
Young Shin Kim, MD PhD
Principal Investigator
University of California, San Francisco
Are You a Good Fit for This Trial?
This trial is for children aged 4-8 with borderline intellectual functioning or mild intellectual disability. They must be able to communicate and participate in tests and activities, and their legal guardians must consent. Children who can't see, hear well, or have been in another drug trial recently can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the D-kit/EF1 program or watch educational videos 5 times a week for 30 minutes each session
Follow-up
Participants are monitored for changes in executive function and cognitive improvement
What Are the Treatments Tested in This Trial?
Interventions
- D-kit/EF1
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
DoBrain Inc.
Industry Sponsor
Korea Health Industry Development Institute
Collaborator